Skip to main content

Table 3 Univariate associations of A_HSCORE of NILCO and targets with TNBC, ER+and ER- breast cancer tissues

From: NILCO biomarkers in breast cancer from Chinese patients

 

Breast cancer

Non-malignant

Antigen

ER- (n=21)

ER+ (n=33)

TNBC (n=13)

P-value*

Hyperplasias (n=3) or Fibroadenomas(n=2)

Notch1

2.6 (2.01-3.19)

2.55 (1.9-3.19)

2.43 (1.68-3.18)

0.743

1.45 (1.04-1.86)

Negative

0 (0)

0 (0)

1 (7.69)

0.194

NA

Positive

21 (100)

33 (100)

12 (92.31)

 

5 (100)

Notch4

1.67 (1–3.48)

1.62 (1–2.9)

1.36 (1–2.87)

0.449

2 (1.23 - 2)

Negative

5 (25)

5 (16.13)

5 (41.67)

0.204

NA

Positive

15 (75)

26 (83.87)

7 (58.33)

 

3 (100)

JAG1

1.23 (1–2.09)

1.37 (1–3)

1.23 (1–2.24)

0.776

1.28 (1.11 - 2.28)

Negative

6 (28.57)

9 (27.27)

4 (30.77)

0.972

NA

Positive

15 (71.43)

24 (72.73)

9 (69.23)

 

5 (100)

DLL4

3.16 (1.91 - 3.66)

3.21 (2–3.87)

2.85 (1.19 - 3.36)

0.028

3.18 (2.59 - 3.68)

Negative

NA

NA

NA

NA

NA

Positive

21 (100)

33 (100)

13 (100)

 

5 (100)

Leptin

2.69 (1–4)

3.16 (1–4)

1.5 (1–3.84)

0.675

1 (1–1.24)

Negative

6 (28.57)

10 (30.3)

5 (38.46)

0.820

3 (60)

Positive

15 (71.43)

23 (69.7)

8 (61.54)

 

2 (40)

OB-R

1.06 (1–2.3)

1.11 (1–2.2)

1.05 (1–2.27)

0.924

1 (1–1.5)

Negative

7 (33.33)

10 (30.3)

5 (38.46)

0.867

4 (80)

Positive

14 (66.67)

23 (69.7)

8 (61.54)

 

1 (20)

IL-1R tI

3.65 (2.55 - 4)

3.72 (2.46 - 4)

3.31 (1–4)

0.027

3.99 (2.74 - 4)

Negative

7 (33.33)

10 (30.3)

5 (38.46)

0.194

NA

Positive

14 (66.67)

23 (69.7)

8 (61.54)

 

4 (100)

VEGF

3.74 (2.22 - 4)

3.67 (2.64 - 4)

3.77 (1.04 - 4)

0.767

3.96 (3.74 - 4)

Negative

NA

NA

NA

NA

NA

Positive

21 (100)

33 (100)

13 (100)

 

5 (100)

VEGFR2

1 (1–2)

1 (1–2)

1 (1–2)

0.506

1 (1–1.1)

Negative

15 (71.43)

20 (60.61)

9 (69.23)

0.685

3 (60)

Positive

6 (28.57)

13 (39.39)

4 (30.77)

 

2 (40)

  1. Data are presented as median (range), and number of positive and negative tissues (%). ER: estrogen receptor; TNBC: triple negative breast cancer; Notch1 and 4: Notch receptor type 1 and 4; JAG1: Jagged1, a Notch ligand; DLL4: Delta like ligand 4, a Notch ligand; OB-R: leptin receptor; IL-1RtI: interleukin 1 receptor type I; VEGF: vascular endothelial growth factor; VEGFR2: vascular endothelial growth factor 2. Numbers in ”bold” show significant differences. *The p-value is calculated by ANOVA for Notch1 and Kruskal-Wallis test for the remaining numerical covariates; chi-square test or Fisher’s exact test for categorical covariates, where appropriate.